New hope for young minds: depression drug trial for children

NCT ID NCT02129751

Not yet recruiting Symptom relief Sponsor: Bausch Health Americas, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether bupropion hydrobromide (Aplenzin) can safely ease depression symptoms in children and adolescents aged 7 to 17. About 246 participants will receive either the drug or a placebo. The main goal is to see if depression scores improve by the end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bupropion hydrobromide (Aplenzin)
What this could lead to: If successful, this could provide a new treatment option for depression in children and adolescents.
What could go wrong: This is a Phase 4 trial, but results may not apply to all ages or severities. Side effects like seizures or mood changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

More trials for these conditions

Other studies related to the condition(s) this trial covers.